Switch theme
Sign up to access all valuation multiples
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
1996
164
LTM Revenue $195M
LTM EBITDA $37.5M
$327M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rigel Pharmaceuticals has a last 12-month revenue (LTM) of $195M and a last 12-month EBITDA of $37.5M.
In the most recent fiscal year, Rigel Pharmaceuticals achieved revenue of $179M and an EBITDA of $28.5M.
Rigel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rigel Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $195M | XXX | $179M | XXX | XXX | XXX |
| Gross Profit | $176M | XXX | $161M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $37.5M | XXX | $28.5M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $32.8M | XXX | $24.2M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $26.6M | XXX | $17.5M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rigel Pharmaceuticals's stock price is $19.
Rigel Pharmaceuticals has current market cap of $343M, and EV of $327M.
See Rigel Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $327M | $343M | XXX | XXX | XXX | XXX | $1.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rigel Pharmaceuticals has market cap of $343M and EV of $327M.
Rigel Pharmaceuticals's trades at 1.8x EV/Revenue multiple, and 11.5x EV/EBITDA.
Equity research analysts estimate Rigel Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rigel Pharmaceuticals has a P/E ratio of 12.9x.
See valuation multiples for Rigel Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $343M | XXX | $343M | XXX | XXX | XXX |
| EV (current) | $327M | XXX | $327M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 11.5x | XXX | XXX | XXX |
| EV/EBIT | 10.0x | XXX | 13.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.9x | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 10.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRigel Pharmaceuticals's last 12 month revenue growth is 15%
Rigel Pharmaceuticals's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.8M for the same period.
Rigel Pharmaceuticals's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rigel Pharmaceuticals's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rigel Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 63% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 0% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rigel Pharmaceuticals acquired XXX companies to date.
Last acquisition by Rigel Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Rigel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rigel Pharmaceuticals founded? | Rigel Pharmaceuticals was founded in 1996. |
| Where is Rigel Pharmaceuticals headquartered? | Rigel Pharmaceuticals is headquartered in United States of America. |
| How many employees does Rigel Pharmaceuticals have? | As of today, Rigel Pharmaceuticals has 164 employees. |
| Who is the CEO of Rigel Pharmaceuticals? | Rigel Pharmaceuticals's CEO is Mr. Raul R. Rodriguez. |
| Is Rigel Pharmaceuticals publicy listed? | Yes, Rigel Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Rigel Pharmaceuticals? | Rigel Pharmaceuticals trades under RIGL ticker. |
| When did Rigel Pharmaceuticals go public? | Rigel Pharmaceuticals went public in 2000. |
| Who are competitors of Rigel Pharmaceuticals? | Similar companies to Rigel Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rigel Pharmaceuticals? | Rigel Pharmaceuticals's current market cap is $343M |
| What is the current revenue of Rigel Pharmaceuticals? | Rigel Pharmaceuticals's last 12 months revenue is $195M. |
| What is the current revenue growth of Rigel Pharmaceuticals? | Rigel Pharmaceuticals revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Rigel Pharmaceuticals? | Current revenue multiple of Rigel Pharmaceuticals is 1.7x. |
| Is Rigel Pharmaceuticals profitable? | Yes, Rigel Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rigel Pharmaceuticals? | Rigel Pharmaceuticals's last 12 months EBITDA is $37.5M. |
| What is Rigel Pharmaceuticals's EBITDA margin? | Rigel Pharmaceuticals's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Rigel Pharmaceuticals? | Current EBITDA multiple of Rigel Pharmaceuticals is 8.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
